These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation. Luciani J; Benalia H; Bitker MO; Mouquet C; Chartier-Kastler E; Ourhama S; Jacobs C; Chatelain C; Viars P Transplant Proc; 1993 Jun; 25(3):2302. PubMed ID: 8516907 [No Abstract] [Full Text] [Related]
24. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
25. Treatment of steroid resistant acute rejection after renal transplantation. Oh CK; Kim YS; Kim MS; Kim SI; Park K Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737 [No Abstract] [Full Text] [Related]
27. Clinical evaluation of cyclosporine monitoring in blood by specific and nonspecific radioimmunoassay methods in renal transplant patients with stable renal function and nephrotoxicity. Sabaté I; Castelao AM; Santos P; Bover J; Martínez JM; Ruiz R; González de la Presa B; Moliner R; Palencia T; Griñó JM Transplant Proc; 1995 Aug; 27(4):2254-5. PubMed ID: 7652796 [No Abstract] [Full Text] [Related]
28. Cytokine-release syndrome: differences between high and low doses of OKT3. Norman DJ; Kimball JA; Barry JM Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420 [No Abstract] [Full Text] [Related]
29. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835 [TBL] [Abstract][Full Text] [Related]
30. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Cecka JM; Gjertson D; Terasaki PI Transplant Proc; 1993 Feb; 25(1 Pt 1):548-9. PubMed ID: 8438408 [No Abstract] [Full Text] [Related]
32. Role of cyclosporine rescue therapy in steroid resistant rejections. Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789 [No Abstract] [Full Text] [Related]
33. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months. Banowsky LH; Wright FH; Kothmann R; Floyd M; Vick S Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175 [No Abstract] [Full Text] [Related]
34. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation. Mestre M; González C; Griño JM; Valls A; Bonete J; Mané E; Corominas M; Bas J; Romeu A; Buendia E Transplant Proc; 1992 Feb; 24(1):73-5. PubMed ID: 1539351 [No Abstract] [Full Text] [Related]
35. Strategy for improving retransplantation in the CyA era. Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292 [No Abstract] [Full Text] [Related]
36. Cytokine nephropathy during antilymphocyte therapy. Batiuk TD; Bennett WM; Norman DJ Transplant Proc; 1993 Apr; 25(2 Suppl 1):27-30. PubMed ID: 8465418 [No Abstract] [Full Text] [Related]
37. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461 [No Abstract] [Full Text] [Related]
38. Incidence and patterns of rejection using different induction therapies in liver transplant recipients. Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835 [No Abstract] [Full Text] [Related]